• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas.

作者信息

Rindone Giovanni, Aroldi Andrea, Bossi Elisa, Verga Luisa, Zambrotta Giovanni, Tarantino Sara, Piazza Rocco, Mussolin Lara, Chiarle Roberto, Gambacorti-Passerini Carlo

机构信息

Hematology Division, San Gerardo Hospital, Monza, Italy.

Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.

出版信息

Blood Adv. 2023 Feb 14;7(3):314-316. doi: 10.1182/bloodadvances.2022007538.

DOI:10.1182/bloodadvances.2022007538
PMID:35914224
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9898594/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bfd/9898594/8d0e46595fea/BLOODA_ADV-2022-007538-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bfd/9898594/678b050ce8f6/BLOODA_ADV-2022-007538-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bfd/9898594/8d0e46595fea/BLOODA_ADV-2022-007538-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bfd/9898594/678b050ce8f6/BLOODA_ADV-2022-007538-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bfd/9898594/8d0e46595fea/BLOODA_ADV-2022-007538-gr2.jpg

相似文献

1
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas.克唑替尼用于复发/难治性ALK阳性淋巴瘤的长期安全性和疗效的单中心分析
Blood Adv. 2023 Feb 14;7(3):314-316. doi: 10.1182/bloodadvances.2022007538.
2
A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.克唑替尼用于复发或难治性间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤的I/II期研究及克唑替尼用于复发或难治性神经母细胞瘤的I期研究：一项多中心单臂开放标签试验的研究方案
Acta Med Okayama. 2018 Aug;72(4):431-436. doi: 10.18926/AMO/56184.
3
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.克唑替尼治疗儿童难治性实体瘤或间变大细胞淋巴瘤的安全性和活性：儿童肿瘤学组 1 期联盟研究。
Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.
4
Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma.克唑替尼与长春碱联合治疗复发或难治性儿童ALK阳性间变性大细胞淋巴瘤。
Haematologica. 2023 May 1;108(5):1442-1446. doi: 10.3324/haematol.2022.281896.
5
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.ALK 激酶结构域的激活突变赋予 NPM-ALK 阳性间变大细胞淋巴瘤对结构上无关的 ALK 抑制剂的耐药性。
J Cancer Res Clin Oncol. 2014 Apr;140(4):589-98. doi: 10.1007/s00432-014-1589-3. Epub 2014 Feb 8.
6
ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.间变性淋巴瘤激酶（ALK）表达在间变性大细胞淋巴瘤中发挥不同作用，以及在中国人群复发/难治性ALK阳性患者中使用克唑替尼的疗效。
Ann Hematol. 2018 Jan;97(1):149-159. doi: 10.1007/s00277-017-3166-8. Epub 2017 Nov 17.
7
Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma.克唑替尼导致一名神经母细胞瘤患儿出现糜烂性食管炎。
J Oncol Pharm Pract. 2019 Apr;25(3):724-726. doi: 10.1177/1078155217752537. Epub 2018 Jan 22.
8
ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.原发性间变性大细胞淋巴瘤中ALK激酶结构域突变：对NPM-ALK活性及酪氨酸激酶抑制剂敏感性的影响
PLoS One. 2015 Apr 13;10(4):e0121378. doi: 10.1371/journal.pone.0121378. eCollection 2015.
9
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.来自欧洲癌症研究与治疗组织（EORTC）90101 CREATE试验的克唑替尼治疗晚期不可切除炎性肌纤维母细胞瘤患者的长期疗效更新
Eur J Cancer. 2021 Oct;156:12-23. doi: 10.1016/j.ejca.2021.07.016. Epub 2021 Aug 13.
10
[Use of crizotinib for refractory ALK-positive lymphomas].克唑替尼用于难治性ALK阳性淋巴瘤的治疗
Ter Arkh. 2017;89(7):51-56. doi: 10.17116/terarkh201789751-56.

引用本文的文献

1
Anaplastic large cell lymphoma in children and adolescents.儿童和青少年间变性大细胞淋巴瘤
Br J Haematol. 2025 Aug;207(2):336-349. doi: 10.1111/bjh.20154. Epub 2025 May 12.
2
ALK in cancer: from function to therapeutic targeting.癌症中的间变性淋巴瘤激酶：从功能到治疗靶点
Nat Rev Cancer. 2025 May;25(5):359-378. doi: 10.1038/s41568-025-00797-9. Epub 2025 Mar 7.
3
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era.靶向药物时代小儿复发性/难治性ALK阳性间变性大细胞淋巴瘤的治疗与转归

本文引用的文献

1
NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.NPM-ALK：淋巴瘤发病机制的驱动因素及治疗靶点
Cancers (Basel). 2021 Jan 5;13(1):144. doi: 10.3390/cancers13010144.
2
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.克唑替尼用于间变性淋巴瘤激酶（ALK）阳性间变性大细胞淋巴瘤化疗复发/难治患者的二期研究。
Am J Hematol. 2020 Dec;95(12):E319-E321. doi: 10.1002/ajh.25967. Epub 2020 Sep 3.
3
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Blood Adv. 2025 Mar 25;9(6):1356-1365. doi: 10.1182/bloodadvances.2024014745.
4
Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma.间变性淋巴瘤激酶阳性淋巴瘤患者在克唑替尼治疗期间成功妊娠
Hematol Oncol. 2025 Jan;43(1):e70038. doi: 10.1002/hon.70038.
5
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies.间变性淋巴瘤激酶（ALK）抑制剂增强了CD47阻断在敏感和耐药的ALK驱动恶性肿瘤中诱导的吞噬作用。
Biomedicines. 2024 Dec 12;12(12):2819. doi: 10.3390/biomedicines12122819.
6
Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.外周T细胞淋巴瘤的进展：发病机制、基因图谱及新兴治疗靶点
Histopathology. 2025 Jan;86(1):119-133. doi: 10.1111/his.15376.
7
Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications.淋巴细胞恶性细胞转化的多样且可重编程机制：发病机制见解与转化意义。
Front Oncol. 2024 Apr 3;14:1383741. doi: 10.3389/fonc.2024.1383741. eCollection 2024.
8
Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.病例报告：克唑替尼和维布妥昔单抗作为自体干细胞移植的桥梁，并随后用于复发/难治性ALK+间变性大细胞淋巴瘤的CD30导向嵌合抗原受体T细胞疗法。
Front Immunol. 2024 Feb 5;15:1346001. doi: 10.3389/fimmu.2024.1346001. eCollection 2024.
9
Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review.间变性淋巴瘤激酶抑制剂诱导的中性粒细胞减少症：一项系统评价。
Cancers (Basel). 2023 Oct 11;15(20):4940. doi: 10.3390/cancers15204940.
10
ALK-positive anaplastic large cell lymphoma in adults.成人ALK阳性间变性大细胞淋巴瘤
Fac Rev. 2023 Aug 25;12:21. doi: 10.12703/r/12-21. eCollection 2023.
间变性大细胞淋巴瘤：当代概念与最佳管理
Cancer Treat Res. 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6.
4
ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.ALK 阳性组织细胞增生症：一个扩展的临床病理谱，并且经常存在 KIF5B-ALK 融合。
Mod Pathol. 2019 May;32(5):598-608. doi: 10.1038/s41379-018-0168-6. Epub 2018 Dec 20.
5
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.贝林妥欧单抗联合化疗治疗 CD30 阳性外周 T 细胞淋巴瘤（ECHELON-2）：一项全球性、双盲、随机、3 期临床试验。
Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.
6
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.意大利关于 brentuximab vedotin 的真实世界经验：40 例复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究结果。
Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.
7
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).国际淋巴瘤工作组共识反应评估标准（RECIL 2017）
Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097.
8
Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report.克唑替尼诱导的中性粒细胞减少症在间变性淋巴瘤激酶阳性非小细胞肺癌患者中的成功管理：一例报告
Case Rep Oncol. 2016 Jan 15;9(1):51-5. doi: 10.1159/000443662. eCollection 2016 Jan-Apr.
9
Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.克唑替尼停药后ALK阳性淋巴瘤的突然复发。
N Engl J Med. 2016 Jan 7;374(1):95-6. doi: 10.1056/NEJMc1511045.
10
Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.对于外周T细胞淋巴瘤的长期预后而言，主要治疗反应而非一线干细胞移植至关重要。
PLoS One. 2015 Mar 27;10(3):e0121822. doi: 10.1371/journal.pone.0121822. eCollection 2015.